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Background: Respiratory support following postoperative extubation is of major importance to prevent hypoxemia
and subsequent respiratory failure and reintubation. High-flow nasal cannula oxygen (HFNC) delivers a flow-dependent
positive airway pressure and improves oxygenation by increasing end-expiratory lung volume. Whether application of
HFNC may have therapeutic advantages over conventional oxygen therapy for respiratory support in the early
postextubation surgical period remains to be established.
Methods/design: The Optiflow for prevention of post-extubation hypoxemia after abdominal surgery (OPERA) trial is
an investigator-initiated multicenter randomized controlled two-arm trial with assessor-blinded outcome assessment,
randomizing 220 patients with intermediate to high risk of pulmonary complications after abdominal surgery to receive
HFNC or conventional oxygen therapy following extubation, stratified by the presence of epidural analgesia and center.
The primary outcome measure is the percentage of patients with postoperative hypoxemia one hour after tracheal
extubation. Secondary outcome measures are postoperative pulmonary complications, need for noninvasive ventilation
and intubation for respiratory failure.
Discussion: The OPERA trial is the first randomized controlled study powered to investigate whether early application
of HFNC following extubation after abdominal surgery prevents against postoperative hypoxemia and pulmonary
complications.
Trial registration: ClinicalTrials.gov Identifier: NCT01887015.
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Recent data suggest that more than 200 million major
surgical procedures are performed worldwide each year
[1]. Postoperative respiratory complications still remain
a frequent problem, thereby increasing postoperative mor-
bidity and mortality, [2] and putting a burden on hospital
length of stay and costs of health care [3].
Respiratory support is of major importance following
extubation to avoid respiratory failure and reintubation.
It has been reported that postoperative hypoxemia com-
plicates between 30% and 50% of cases after abdominal
surgery, even among those undergoing uneventful pro-
cedures [4,5]. After extubation and with spontaneous
breathing at ambient air, derecruitment of lung areas
and loss of functional alveolar units may rapidly occur
leading to hypoxemia [6]. Supplemental oxygen adminis-
tration, usually by the use of nasal prongs or a facemask,
is required to ensure adequate arterial oxygenation after
extubation [7]. However, although oxygen therapy is ef-
fective in treating most cases of postoperative hypoxemia
[8], low ventilation-perfusion ratios may be only partially
responsive to an increase in oxygen concentration [9]. In
addition, oxygen therapy is only a symptomatic approach
and is ineffective to compensate for loss in lung volume.
In contrast, the noninvasive application of continuous
positive airway pressure is effective to maintain lung vol-
ume and to improve gas exchange after major surgery [10].
A randomized controlled study authored by Squadrone
and colleagues [11] demonstrated that application of con-
tinuous positive airway pressure (CPAP) may reduce the
need for reintubation, pneumonia and postoperative sepsis
in patients who developed acute hypoxemia (defined as an
arterial oxygen tension to inspiratory oxygen fraction ratio
(PaO2/FiO2) of 300 mmHg or less) after elective major
abdominal surgery. However, patient cooperation and tol-
erance, air leaks and gastric distension are crucial for appli-
cation and success of CPAP or noninvasive ventilation
(NIV). Moreover, NIV affects health-care utilization, since
its application usually requires admission to intensive care
or within care structures capable of providing high levels
of monitoring.
High-flow nasal cannula (HFNC), which delivers high-
flow heated and humidified oxygen and air via nasal
prongs at a prescribed fraction of inspired oxygen and a
maximum flow of 60 L/min, is an attractive alternative
to conventional oxygen therapy [12,13]. Previous stud-
ies have shown that HNFC oxygen therapy generates a
flow-dependent positive airway pressure [13,14] and im-
proves oxygenation by increasing end-expiratory lung
volume, thus suggesting a possible alveolar recruitment
associated with high-flow therapy [15]. Although prophy-
lactic use of HFNC may have potential therapeutic advan-
tages over conventional oxygen therapy for respiratory
support after extubation, evaluation is limited in the earlypost-extubation surgical period and benefit remains to be
established.
The OPERA study aims to compare the effects of early
application of HFNC oxygen therapy and conventional
oxygen administration after extubation on postoperative
pulmonary complications in patients with intermediate




The Optiflow for prevention of post-extubation hypoxemia
after abdominal surgery (OPERA) study is an investigator-
initiated multicenter randomized controlled two-arm trial.
The Institutional Review Board of the University Hospital
of Clermont-Ferrand (France) approved the trial. By April
25 2013, the study had been approved by all centers
by a central ethics committee (Comité de Protection des
Personnes Sud-Est VI, Clermont-Ferrand, France) with
the registration number IDRCB 2013-A00030-45. The
OPERA study is conducted in accordance with the dec-
laration of Helsinki and was registered on June 24 2013
at http://www.clinicaltrials.gov with trial identification
number NCT01887015.
CONSORT diagram
Figure 1 shows the CONSORT diagram of the OPERA
trial.
Study population
Local investigators screen consecutive patients sched-
uled for planned or unplanned abdominal or abdominal
and thoracic surgery with an expected duration of two
hours or more in participating centers. Patients with
intermediate to high risk for postoperative pulmonary
complications following abdominal surgery with gen-
eral anesthesia are eligible for participation. To iden-
tify such patients, the ARISCAT risk score will be used
[16]. An ARISCAT risk score ≥26 is associated with an
intermediate to high risk for postoperative pulmonary
complications.
Patients fulfilling one or more of the following criteria
will not be included: lack of informed consent prior
to randomization (for an unplanned surgical procedure
consent is obtained from the next of kin), nonadult
patients (age <18 years), patients with a body mass
index ≥35 kg/m2, a life-threatening condition requiring
emergency surgery, patients with obstructive sleep apnea,
and pregnant patients to provide a relatively homogenous
study population and avoid potential confounding in the
interpretation.
All patients are asked for signed informed consent, as
required by the institutional review board in accordance
with the Declaration of Helsinki.
Patients scheduled for planned or unplanned abdominal or abdominal
and thoracic surgery (with an expected duration of more than 2 hours)
at intermediate or high risk of postoperative pulmonary complications
Informed consent before surgery 




Standard oxygen therapy 
after extubation (up to Day-1)
110 patients
HFNC oxygen therapy 
after extubation (up to Day-1)
110 patients
Oxygen flow rate adapted 
to maintain SpO2 95%
Flow rate of 50-60 L/min
FiO2 adapted to maintain 
SpO2 95%
Postoperative follow-up
daily up to postoperative Day-7 and until hospital discharge  
Figure 1 CONSORT diagram of the OPERA trial.
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Randomization is performed using a dedicated central-
ized telephone system, accessible round the clock, and
using a computer-generated allocation sequence. The
randomization sequence is generated using random blocks
and is stratified per center and according to the planned
use or nonuse of postoperative epidural analgesia, which is
a factor that may influence outcomes [17]. No blocking is
applied to other trial factors.
Trial interventions
Patients eligible for inclusion following extubation after
abdominal surgery are randomly assigned to standard
oxygen therapy via either nasal prongs or face mask with
oxygen flow titrated by the bedside clinician to maintain
a peripheral oxygen saturation of 95% or more, or HFNC
oxygen therapy at a flow rate of 50 to 60 L/min and FiO2
titrated by the bedside clinician to maintain a peripheral
oxygen saturation of 95% or more. In each group, extu-
bation criteria after surgery are: recovery of spontaneous
ventilation with an expired tidal volume between 5 and 8
ml/kg, respiratory rate between 12 and 25 breaths/min, ab-
sence of residual neuromuscular blockade (assessed by a
T4/T1 ratio ≥90%), peripheral oxygen saturation ≥95%,
stable hemodynamics and a body temperature ≥36°C.
HFNC oxygen therapy is delivered via the Optiflow™
system (Fisher & Paykel Healthcare Ltd, Auckland, NewZealand) using a MR850 heated humidifier and a RT202
breathing circuit. Allocated therapy is delivered until 0700
to 0800 hours postoperative day 1 at which time point
study therapy is discontinued and requirement for supple-
mental oxygen therapy is assessed.
Standard procedures
The recently completed Intraoperative Protective Venti-
lation (IMPROVE) trial showed significantly improved
clinical outcomes (10.5% versus 27.5%, P <0.001) in pa-
tients who received intraoperative lung-protective mechan-
ical ventilation compared with those receiving NIV [18].
Therefore, the study protocol stresses that intraoperative
lung-protective mechanical ventilation must be used in the
OPERA trial.
All other aspects of patient care during the intra- and
postoperative periods, including general anesthesia, fluid
administration, prophylactic antibiotics and postoperative
pain management, are conducted by the attending phys-
ician according to the expertise of the staff at each center
and routine clinical practice. However, it is suggested to
perform postoperative pain management to achieve a vis-
ual numerical scale (VNS) pain score <3, to avoid excessive
administration of intraoperative fluids (according to the
discretion of the attending anesthesiologist), and to use ap-
propriate prophylactic antibiotics. Data on the applied pro-
cedures will be collected and analyzed.
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Primary outcome variable is the percentage of patients
who developed postoperative hypoxemia one hour after
tracheal extubation. Postoperative hypoxemia is defined
as PaO2/FiO2 ratio <300, as used previously [11].
Secondary outcome variables are postoperative gas ex-
change one hour after extubation and after discontinu-
ation of the allocated treatment, respiratory discomfort
(using a numerical rating scale, ranging from 0 to 10),
need for supplemental oxygen therapy (defined as arter-
ial oxygen saturation <93% on room air), need for post-
operative reintubation and/or NIV for acute respiratory
failure within the first seven days after surgery, postopera-
tive pulmonary complications within the first seven days
after surgery, unexpected intensive care unit (ICU) admis-
sion or readmission, ICU and hospital length of stays, and
in-hospital mortality. Acute respiratory failure is defined by
one of the hypoxemic criteria (peripheral oxygen saturation
(SpO2) <92% while breathing at least 10 L/min oxygen,
PaO2 <60 mmHg on air or PaO2 <80 mmHg while breath-
ing any supplemental oxygen) and at least one of the fol-
lowing criteria: severe respiratory distress with dyspnea,
accessory muscle recruitment and paradoxical abdominal
or thoracic motion, respiratory rate >25 breaths/min,
respiratory acidosis with pH <7.30 and arterial carbon di-
oxide partial pressure (PaCO2) >50 mmHg [19]. Postopera-
tive pulmonary complications are scored with the use of a
graded scale [20] from 0 (no pulmonary complications) to
4 (the most severe complications). Postoperative pulmon-
ary complications are defined as: atelectasis (opacification
of the lung with shift of the mediastinum, hilum or hemi-
diaphragm toward the affected area and compensatory
overinflation in the adjacent nonatelectatic lung); suspected
pulmonary infection (patient receives antibiotics and meets
at least one of the following criteria: new or changed spu-
tum, new or changed lung opacities on chest X-ray when
clinically indicated, tympanic temperature >38.3°C, white
blood cell (WBC) count >12,000/μl in the absence of other
infectious focus); pleural effusion (chest X-ray demon-
strating blunting of the costophrenic angle, loss of the
sharp silhouette of the ipsilateral hemidiaphragm in up-
right position, evidence of displacement of adjacent ana-
tomical structures or (in supine position) a hazy opacity
in one hemithorax with preserved vascular shadows); and
pneumothorax (air in the pleural space with no vascular
bed surrounding the visceral pleura).
Blinding
A computer program will generate the coding list and
will allocate coding numbers to patients from the spe-
cific trial site. It is not feasible to mask the assigned oxygen
therapy from the attending anesthesiologists, since they
have an ethical responsibility to ensure patient safety until
discharge from the post-anesthesia care unit. However, ineach participating center, postoperative data will be col-
lected and recorded onto case report forms (CRFs) by local
research coordinators blinded to the randomized interven-
tion. A trained research coordinator, blinded to the ran-
domized intervention, will centralize data from all sites and
will record them onto the electronic database.
Suspension of protocol
The protocol may be suspended for the individual pa-
tient at the discretion of the attending anesthesiologist if
the patient is to be intubated in the presence of acute re-
spiratory failure. In case of severe respiratory discomfort
with the assigned therapy, the protocol may be tempor-
arily suspended. The protocol will be resumed promptly
after resolution of symptoms. These patients will be ana-
lyzed according to their originally assigned groups on an
intention-to-treat basis.
Statistics
For this study, 2 × 110 patients are needed to detect a
50% relative difference in the primary outcome, at a
two-sided α level of 0.05 and a statistical power of 90%,
assuming a 40% rate of postoperative hypoxemia in the
standard oxygen therapy group [4,5]. An interim analysis
is planned after enrollment of the first 110 patients to
review data relating to patient safety and quality of trial
conduct using the Lan and DeMets method (East soft-
ware, Cytel Inc., Cambridge, MA, USA). The data and
monitoring safety committee will recommend stopping
the trial if the continued conduct of the trial compro-
mises patient safety (a between-group difference in ser-
ious adverse events is found).
Statistical analysis will be conducted on an intention-
to-treat (ITT) basis. Unadjusted chi-square or Fisher’s
exact test will be used for primary outcome analysis. Ad-
justed analysis will be performed with the use of robust
random effects Poisson generalized linear regression (1) to
take into account adjustment on possible confounding co-
variates selected according to clinical relevance and (2) to
consider within and between center variability. All effect
sizes will be presented with 95% confidence intervals. The
chi-square test (or Fisher’s exact test as appropriate) will be
used for secondary binary outcomes. Continuous variables
will be compared with the use of the unpaired t test or the
Mann–Whitney U test when appropriate. The Shapiro-
Wilk test will be used to assess normality, and the Fisher-
Snedecor test to assess homoscedasticity. Adjusted analyses
will be performed using the same adjustment variables, de-
scribed previously, in the linear regression model. The
time-to-event curves should be calculated with the use of
the Kaplan-Meier method. If the frequency of missing data
is >5%, an additional analysis will be performed using the
multiple imputation method (STATA command mi) [21].
Longitudinal analysis using mixed models will be used to
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All analyses will be conducted with Stata statistical soft-
ware, version 12 (StataCorp LP, College Station, TX, USA).
A two-sided P value of less than 0.05 will be considered to
indicate statistical significance.
Registration
Data will be collected and recorded onto CRFs in each
center by trained local research coordinators blinded to
the randomized intervention. A trained research coord-
inator will centralize data from all sites and will record
them onto the electronic database.
The following data will be collected and registered
Prerandomization and baseline characteristics: gender,
age, height, weight, ideal body weight, physical status
(according to the American Society of Anesthesiology
status score), cardiac status (hypertension, cardiac failure,
ischemic heart disease), respiratory status (history of
chronic obstructive pulmonary disease, asthma status, re-
spiratory infection in the last month, long-term home
oxygen therapy), smoking status, alcohol status, history
of diabetes mellitus, recent denutrition (defined as weight
loss >10% in the last six months and/or plasma albu-
min <30 g/l), history of renal insufficiency, ARISCAT
score, preoperative SpO2, and blood samples (WBC
count, hematocrit, hemoglobin, platelet count, prothrom-
bin time, fibrinogen, urea, creatinine, C reactive protein
and albumin).
During the surgical and anesthesia procedures: type of
surgery (planned or unplanned), surgical site (abdominal
or abdominal and thoracic), surgical technique (laparotomy
or laparoscopy), duration of both anesthesia and surgical
procedures, blood losses, transfusion requirement, all ad-
ministered drugs during anesthesia (anesthetics, vasoactive
drugs, neuromuscular blocking agent), all administered
fluid (crystalloid, colloid), ventilator settings (tidal volume,
positive end-expiratory pressure, recruitment maneuver,
FiO2, plateau and peak pressures), duration of mechanical
ventilation.
From randomization to postoperative day 1 (at which
time point study therapy is discontinued): vital parame-
ters, SpO2, visual analog scale (VAS) score for pain, VNS
score for respiratory discomfort, arterial blood gases
(PaO2, PaCO2, pH, bicarbonate test (HCO3), arterial
oxygen saturation (SaO2)), all side effects related to the
allocated oxygen therapy, presence or absence of postop-
erative pulmonary complications.
Daily from postoperative day 1 to day 7: vital parameters,
need for supplemental oxygen administration, presence
or absence of postoperative pulmonary complications
(pulmonary complication, if present, is graded), chest-X
ray when clinically indicated, need for intubation or nonin-
vasive mechanical ventilation, need for ICU admission orreadmission. The day of development of any pulmonary
complication and/or ICU admission is indicated.
The day of hospital discharge: duration of ICU and
hospital stays, survival status (the day of death, if present,
is indicated).
Data handling and record keeping
Data will be handled according to French law. All original
records (including consent forms, CRFs and relevant cor-
respondence) will be archived at trial sites for 15 years.
The clean database file will be anonymized and maintained
for 15 years.
Study organization
The study is an investigator-initiated trial. Study promotion
is performed by Clermont-Ferrand University Hospital,
Clermont-Ferrand, France. There is no industry support or
involvement in the trial.
Duration and timeline
Patients from three French University Teaching Hospi-
tals are expected to be included during a two-year inclu-
sion period starting September 2013.
2013: Protocol, approvals from ethics committee, and
trial tool development (CRF, randomization system).
2013 to 2014: Inclusion of patients.
2014: Cleaning and closure of the database. Data ana-
lyses and writing of the manuscript, and submission for
publication.
Discussion
It has become clear that postoperative pulmonary com-
plications are the main source of postoperative morbid-
ity and mortality [2,22]. Optimizing respiratory support
is, therefore, of particular importance during the peri-
operative period, especially in patients with high risk of
pulmonary complications. The OPERA trial is the first
randomized controlled study powered to investigate early
application of HFNC oxygen therapy in patients scheduled
for abdominal surgery with intermediate to high risk of
pulmonary complications.
The primary endpoint of the trial is postoperative hyp-
oxemia, which could be seen as a shortcoming since cor-
rection of hypoxemia is only purely symptomatic and
does not always improves postoperative outcomes of
surgical patients. The incidence of postoperative hypox-
emia is particularly high in surgical patients, reaching up
to 50% [4,5]. The ability to anticipate and to provide
early treatment to potentially modifiable adverse clinical
events such as postoperative hypoxemia is of critical im-
portance to prevent the development of subsequent com-
plications. Moreover, since we collect and report on most
postoperative pulmonary complications, it may still be pos-
sible to determine the effects on other complications.
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spiratory support therapy in the postoperative period is
of particular importance to design individually tailored
management approaches. In this study, we use the
ARISCAT score [16] to assess the individual predictive risk
of postoperative pulmonary complications, and the focus
is on investigating patients with intermediate to high risk
of complications. The ARISCAT score includes seven in-
dependent risk factors (four patient-related risk factors
and three related to the surgical procedure, accounting for
55% and 45% of the score respectively), with the most rele-
vant cut point being the risk score of 26.
Several confounding factors, such as postoperative pain
management, intraoperative fluid administration and re-
spiratory chest physiotherapy, can be suggested. These
points are not protocolized in the OPERA trial, in con-
trast to the management of intraoperative mechanical
ventilation. Nevertheless, the study protocol stresses that
intra- and postoperative care are to be performed in ac-
cordance with each center’s specific expertise to make
the trial as close as possible to routine clinical care.
In conclusion, the OPERA trial is an investigator-
initiated pragmatic randomized controlled trial powered
to test the hypothesis that early application of HFNC
prevents postoperative hypoxemia in patients with inter-
mediate to high risk of postoperative pulmonary compli-
cations. The OPERA trial also determines the effects of
high-flow oxygen therapy on most of the postoperative
pulmonary complications, need for noninvasive mechan-
ical ventilation or intubation for postoperative respira-
tory failure, and lengths of ICU and hospital stays.
Trial status
The trial is ongoing and is actively enrolling.
Abbreviations
CPAP: Continuous positive airway pressure; CRF: Case report form;
HCO3: Bicarbonate test; HFNC: High-flow nasal cannula oxygen therapy;
NIV: Noninvasive ventilation; PaCO2: Arterial carbon dioxide partial pressure;
PaO2/FiO2: Arterial oxygen tension to inspiratory oxygen fraction ratio;
SaO2: Arterial oxygen saturation; SpO2: Peripheral oxygen saturation;
VAS: Visual analog scale; VNS: Visual numerical scale; WBC: White blood cell.
Competing interests
SJ received grants from Fisher & Paykel France for consulting. The other
authors declare that they have no competing interests.
Authors’ contributions
EF drafted the manuscript together with SJ and CPB. EF designed the study
together with SJ, CPB and JMC. BP planned the statistical analysis. All authors
read and approved the final manuscript.
Acknowledgements
We wish to thank the following: clinical staff at all trial sites. The OPERA trial
is funded by the University Hospital of Clermont-Ferrand, Clermont-Ferrand,
France.
Author details
1Department of Anesthesiology and Critical Care Medicine, Estaing Hospital,
University Teaching Hospital of Clermont-Ferrand, 1, place Lucie Aubrac,63000 Clermont-Ferrand Cedex 1, France. 2Department of Anesthesiology
and Critical Care Medicine B (DAR B), Saint-Eloi Hospital, University Teaching
Hospital of Montpellier, 80 avenue Augustin Fliche, 34295 Montpellier,
France. 3Department of Anesthesiology and Critical Care Medicine, AP-HP
Beaujon Hospital, 100, boulevard du Général Leclerc, 92118 Clichy, France.
4Biostatistics Unit, Direction de la Recherche Clinique (DRCI), 58 rue
Montalembert, 63003 Clermont-Ferrand, France.
Received: 6 August 2013 Accepted: 4 October 2013
Published: 18 October 2013References
1. Weiser TG, Regenbogen SE, Thompson KD, Haynes AB, Lipsitz SR, Berry WR,
Gawande AA: An estimation of the global volume of surgery: a
modelling strategy based on available data. Lancet 2008, 372:139–144.
2. Khuri SF, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ:
Determinants of long-term survival after major surgery and the adverse
effect of postoperative complications. Ann Surg 2005, 242:326–341.
3. Shander A, Fleisher LA, Barie PS, Bigatello LM, Sladen RN, Watson CB: Clinical
and economic burden of postoperative pulmonary complications: patient
safety summit on definition, risk-reducing interventions, and preventive
strategies. Crit Care Med 2011, 39:2163–2172.
4. Arozullah AM, Daley J, Henderson WG, Khuri SF: Multifactorial risk index for
predicting postoperative respiratory failure in men after major noncardiac
surgery. The national veterans administration surgical quality improvement
program. Ann Surg 2000, 232:242–253.
5. Lawrence VA, Dhanda R, Hilsenbeck SG, Page CP: Risk of pulmonary
complications after elective abdominal surgery. Chest 1996, 110:744–750.
6. Lindberg P, Gunnarsson L, Tokics L, Secher E, Lundquist H, Brismar B,
Hedenstierna G: Atelectasis and lung function in the postoperative
period. Acta Anaesthesiol Scand 1992, 36:546–553.
7. Rosenberg J, Oturai P, Erichsen CJ, Pedersen MH, Kehlet H: Effect of general
anesthesia and major versus minor surgery on late postoperative
episodic and constant hypoxemia. J Clin Anesth 1994, 6:212–216.
8. Fu ES, Downs JB, Schweiger JW, Miguel RV, Smith RA: Supplemental
oxygen impairs detection of hypoventilation by pulse oximetry.
Chest 2004, 126:1552–1558.
9. Whiteley JP, Gavaghan DJ, Hahn CE: Variation of venous admixture, SF6
shunt, PaO2, and the PaO2/FIO2 ratio with FIO2. Br J Anaesth 2002,
88:771–778.
10. Jaber S, Chanques G, Jung B: Postoperative noninvasive ventilation.
Anesthesiology 2010, 112:453–461.
11. Squadrone V, Coha M, Cerutti E, Schellino MM, Biolino P, Occella P, Belloni G,
Vilianis G, Fiore G, Cavallo F, Ranieri VM: Continuous positive airway pressure
for treatment of postoperative hypoxemia: a randomized controlled trial.
JAMA 2005, 293:589–595.
12. Chanques G, Constantin JM, Sauter M, Jung B, Sebbane M, Verzilli D,
Lefrant JY, Jaber S: Discomfort associated with underhumidified high-
flow oxygen therapy in critically ill patients. Intensive Care Med 2009,
35:996–1003.
13. Chanques G, Riboulet F, Molinari N, Carr J, Jung B, Prades A, Gallia F, Futier E,
Constantin JM, Jaber S: Comparison of three high flow oxygen therapy
delivery devices: a clinical physiological cross-over study. Minerva Anestesiol
2013. Epub ahead of print.
14. Parke R, McGuinness S, Eccleston M: Nasal high-flow therapy delivers low
level positive airway pressure. Br J Anaesth 2009, 103:886–890.
15. Corley A, Caruana LR, Barnett AG, Tronstad O, Fraser JF: Oxygen delivery
through high-flow nasal cannulae increase end-expiratory lung volume
and reduce respiratory rate in post-cardiac surgical patients. Br J Anaesth
2011, 107:998–1004.
16. Canet J, Gallart L, Gomar C, Paluzie G, Valles J, Castillo J, Sabate S, Mazo V,
Briones Z, Sanchis J: Prediction of postoperative pulmonary complications
in a population-based surgical cohort. Anesthesiology 2010, 113:1338–1350.
17. Popping DM, Elia N, Marret E, Remy C, Tramer MR: Protective effects of
epidural analgesia on pulmonary complications after abdominal and
thoracic surgery: a meta-analysis. Arch Surg 2008, 143:990–999.
18. Futier E, Constantin JM, Paugam-Burtz C, Pascal J, Eurin M, Neuschwander A,
Marret E, Beaussier M, Gutton C, Lefrant JY, Allaouchiche B, Verzilli D, Leone M,
De Jong A, Bazin JE, Pereira B, Jaber S: A trial of intraoperative low tidal
volume in abdominal surgery. N Engl J Med 2013, 369:428–437.
Futier et al. Trials 2013, 14:341 Page 7 of 7
http://www.trialsjournal.com/content/14/1/34119. Jaber S, Delay JM, Chanques G, Sebbane M, Jacquet E, Souche B, Perrigault PF,
Eledjam JJ: Outcomes of patients with acute respiratory failure after
abdominal surgery treated with noninvasive positive pressure ventilation.
Chest 2005, 128:2688–2695.
20. Hulzebos EH, Helders PJ, Favie NJ, De Bie RA, de la Brutel RA, Van Meeteren NL:
Preoperative intensive inspiratory muscle training to prevent postoperative
pulmonary complications in high-risk patients undergoing CABG surgery: a
randomized clinical trial. JAMA 2006, 296:1851–1857.
21. Royston P: Multiple imputation of missing values. Stata J 2004, 4:227–241.
22. Thompson JS, Baxter BT, Allison JG, Johnson FE, Lee KK, Park WY: Temporal
patterns of postoperative complications. Arch Surg 2003, 138:596–602.
doi:10.1186/1745-6215-14-341
Cite this article as: Futier et al.: The OPERA trial - comparison of early
nasal high flow oxygen therapy with standard care for prevention of
postoperative hypoxemia after abdominal surgery: study protocol for a
multicenter randomized controlled trial. Trials 2013 14:341.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
